[go: up one dir, main page]

IN2014DN07875A - - Google Patents

Info

Publication number
IN2014DN07875A
IN2014DN07875A IN7875DEN2014A IN2014DN07875A IN 2014DN07875 A IN2014DN07875 A IN 2014DN07875A IN 7875DEN2014 A IN7875DEN2014 A IN 7875DEN2014A IN 2014DN07875 A IN2014DN07875 A IN 2014DN07875A
Authority
IN
India
Prior art keywords
peptide
therapeutic agent
ssvlyggppsaa
histone
conjugate
Prior art date
Application number
Inventor
Shuji Sato
Takeshi Goto
Naoya Ohmori
Kueichen Chiang
Yayoi Shimada
Masafumi Inomata
Toru Kusano
Takahiro Hiratsuka
Takayuki Noguchi
Satoshi Hagiwara
Original Assignee
Josai University Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Josai University Corp filed Critical Josai University Corp
Publication of IN2014DN07875A publication Critical patent/IN2014DN07875A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to a therapeutic agent for histone-induced inflammation said therapeutic agent comprising a monoclonal antibody or an antigen binding fragment thereof which can bind to a peptide comprising an amino acid sequence represented by SSVLYGGPPSAA (SEQ ID NO:1) or a conjugate of said peptide with a pharmaceutically acceptable carrier.
IN7875DEN2014 2012-02-22 2013-02-22 IN2014DN07875A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012035965A JP2015117181A (en) 2012-02-22 2012-02-22 Sepsis therapeutic agent
PCT/JP2013/054551 WO2013125687A1 (en) 2012-02-22 2013-02-22 Therapeutic agent for inflammatory disease

Publications (1)

Publication Number Publication Date
IN2014DN07875A true IN2014DN07875A (en) 2015-04-24

Family

ID=49005863

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7875DEN2014 IN2014DN07875A (en) 2012-02-22 2013-02-22

Country Status (8)

Country Link
US (2) US20150079090A1 (en)
EP (1) EP2815763B1 (en)
JP (1) JP2015117181A (en)
KR (1) KR102159412B1 (en)
CN (1) CN104379165B (en)
IN (1) IN2014DN07875A (en)
TW (1) TWI605059B (en)
WO (1) WO2013125687A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103534271B (en) 2010-08-20 2016-06-22 学校法人城西大学 Monoclonal antibodies or antigen-binding fragments thereof with immunosuppressive activity
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CA3019560A1 (en) * 2016-03-29 2017-10-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
JP6656677B2 (en) * 2016-09-23 2020-03-04 ティーエフケイ株式会社 Compound or salt thereof, anti-inflammatory agent, anticancer agent for lung cancer, method for producing compound or salt thereof, method for treating inflammatory disease, and method for treating lung cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070073754A (en) * 2004-09-03 2007-07-10 아마테라스파마 가부시키가이샤 Anti-histone H1 monoclonal antibody and hybridomas capable of producing it
JPWO2009044555A1 (en) * 2007-10-04 2011-02-03 学校法人 城西大学 Formulation, vaccine administration method and iontophoresis device using the formulation
US8716218B2 (en) * 2007-11-06 2014-05-06 Oklahoma Medical Research Foundation Extracellular histones as biomarkers for prognosis and molecular targets for therapy
CN103534271B (en) * 2010-08-20 2016-06-22 学校法人城西大学 Monoclonal antibodies or antigen-binding fragments thereof with immunosuppressive activity

Also Published As

Publication number Publication date
EP2815763B1 (en) 2018-06-13
TW201350502A (en) 2013-12-16
US20170096478A1 (en) 2017-04-06
CN104379165A (en) 2015-02-25
JP2015117181A (en) 2015-06-25
KR102159412B1 (en) 2020-09-23
US20150079090A1 (en) 2015-03-19
EP2815763A4 (en) 2015-07-22
WO2013125687A1 (en) 2013-08-29
EP2815763A1 (en) 2014-12-24
TWI605059B (en) 2017-11-11
CN104379165B (en) 2018-08-03
KR20140138699A (en) 2014-12-04

Similar Documents

Publication Publication Date Title
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
PH12014500089A1 (en) Antibodies that bind to ox40 and their uses
TN2014000120A1 (en) Cd27l antigen binding proteins
MX2014005108A (en) Polypeptide constructs and uses thereof.
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
NZ607969A (en) Cd33 binding agents
IN2014KN01715A (en)
PH12014501783B1 (en) Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody
UA111818C2 (en) ANTIBODY AGAINST CSF-1R
NZ607710A (en) 4-1bb binding molecules
MX2014001375A (en) Pharmaceutical composition for treatment and/or prophylaxis of cancer.
AR096364A1 (en) ANTITRANSPHERINE RECEIVING ANTIBODIES AND METHODS OF USE
MX357193B (en) Anti-alpha synuclein binding molecules.
MX340014B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX2012008998A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX2012009000A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX340016B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
NZ630847A (en) Anti-sema4d antibodies and epitopes
SG178886A1 (en) Humanized anti-cdcp1 antibodies
UA113623C2 (en) TISSUE FACTOR FACTOR (TFPI) MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EA201270701A1 (en) INHIBITING METAL PROTEINS ANTIBODIES
IN2014DN07875A (en)
IN2013MN00513A (en)